key: cord-0961977-tyvsl7os authors: Yarza, Ramón; Bover, Mateo; Paredes, Diana; López-López, Flora; Jara-Casas, Diego; Castelo-Loureiro, Alicia; Baena, Javier; Mazarico, José María; Folgueira, María Dolores; Meléndez-Carmona, María Ángeles; Reyes, Alhena; Lumbreras, Carlos; Paz-Ares, Luis; Díaz-Pedroche, Carmen; Gómez-Martín, Carlos title: Sars-CoV-2 infection in cancer patients undergoing active treatment. Analysis of clinical features and predictive factors for severe respiratory failure and death date: 2020-06-06 journal: Eur J Cancer DOI: 10.1016/j.ejca.2020.06.001 sha: 34417e7d5567385577929d30c9b65d1d20fe2580 doc_id: 961977 cord_uid: tyvsl7os AIM: Previous studies have suggested a more frequent and severe course of novel coronavirus Sars-coV-2 infection in cancer patients undergoing active oncologic treatment. Our aim was to describe the characteristics of the disease in this population and to determine predictive factors for poor outcome in terms of severe respiratory distress (ARDS) or death. PATIENTS AND METHODS: Patients consecutively admitted for SARS-CoV-2 infection were prospectively collected and retrospective statistical analysis was performed. Univariate and multivariate analyses were performed to assess potential factors for poor outcomes defined as ARDS or death. RESULTS: 63 patients were analyzed, 34 of them developed respiratory failure (70% as ARDS). Lymphocytes/mm3 (412 vs. 686; p=0.001), serum albumin (2.84 vs. 3.1); LDH (670vs. 359; p<0.001) and C-Reactive Protein (CRP) levels (25.8 vs. 9.9; p<0.001) discriminate those that developed respiratory failure. Mortality Rate was 25%, significantly higher among ARDS, neutropenic patients (p=0.01) and in those with bilateral infiltrates (44% vs. 0%; p<0.001). Multivariate logistic analyses model confirmed the predictive value of severe neutropenia (OR 16.54 CI 95% 1.43-190.9, p 0.025), bilateral infiltrates (OR 32.83, CI95% 3.51-307, p 0.002) and tumor lung involvement (OR 4.34, CI95% 1.2-14.95, p 0.02). CONCLUSION: Cancer patients under active treatment admitted for Sars-coV2 infection have worse outcomes in terms of mortality and respiratory failure rates compared with COVID-19 global population. Lymphopenia, LDH, CRP and albumin discriminate illness severity while neutropenia; bilateral infiltrates and tumor pulmonary involvement are predictive of higher mortality. , the spread of this disease to the rest of the world including Europe and the United States of America (2) led the WHO to declare the infection caused by SARS-CoV2 a public health emergency of international concern in Marc, 11 th 2020 (3) . SARS-CoV-2 infection ranges from asymptomatic course to severe lower respiratory tract infection with pulmonary infiltrates that could evolve to acute respiratory distress syndrome (ARDS) and death. Cancer patients, especially those undergoing active oncologic, could represent a more vulnerable group among infected population. Only a few case series or retrospective studies have been published so far with limited clinical information and small sample size. Specific data regarding cancer history, antitumor treatment, respiratory course, laboratory testing and mortality rates are scant (4, 5) . Despite patients receiving active anticancer treatment are clearly underreported in those papers aforementioned, they agree in a higher incidence of infection and risk of severe events among cancer patients (6) . The objective of this work was to decribe the characteristics, clinical manifestations, course and outcomes of patients under active antitumor treatment admitted due to SARS-CoV2 infection and also to determine predictive factors of poor outcome in this specific population. Since March 9 th , on-site active screening for patients attending our Outpatient clinic and Oncologic Urgent Care Unit was implemented. Until April 19 th , 287 patients had been screened by means of clinical assessment, chest X-ray imaging, complete blood test and a nasopharygeal swab for specific RT-PCR for SARS-CoV-2. SARS-CoV-2 confirmed cases were considered those with positive testing by RT-PCR following WHO recommendations for viral testing in either nasopharyngeal swab or sputum. Highly suspicious patients were considered those with symptoms, blood testing results as well as radiological infiltrates consistent with viral pneumonia despite two consecutively negative RT-PCR results. Patients showing radiologically proven pneumonia as well as those presenting with hypoxemia (defined as arterial pO2<80 mmHg) were admitted. Patients underwent complete medical exam followed by complete blood testing, EKG and chest X-ray at admission. Lab testing was repeated every 24 or 48 hours including complete blood count, serum biochemistry (including renal and liver function testing, lactate dehydrogenase -LDH-levels, C reactive protein levels CRP-and ferritin) as well as coagulation profile (including fibrinogen and D-Dimer -DD-levels). Interleuquin-6 (IL-6) was only measured at the time of admission as well as in case of respiratory deterioration. Specific treatment for viral infection was started according to the limited medical evidence at the time of admission and reviewed in a timely manner: in case of no contraindication, Lopinavir/Ritonavir (LPV/r), hydroxicloroquine (HCQ) and azithromycin (AZ), triple therapy was initiated. After the results of Cao B. and colleagues (7) , patients were treated with HCQ (8, 9) and AZ alone. In selected cases with ARDS and/or hyperinflammatory patient condition defined by high ferritin, D-Dimers and CRP serum levels, Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6) was employed as previously described (10) . Metastatic status was divided in patients with either 1 metastatic location (oligometastatic) or ≥ 2metastatic locations (polymetastatic). Pulmonary Tumor Involvement was considered in case of documented lung metastases or a primary lung cancer. Active oncologic treatment was defined as any antitumor therapy administered within 4 weeks prior to admission. Oncologic treatment was divided according to its main components into highly myelosuppressant or non-myelosuppressant, chemotherapy regimens, endocrine therapy, target therapy and immunotherapy (antiPD1 or antiCTLA4 drugs). ECOG score was evaluated at the moment of admission. Time to death is defined as number of days since beginning of the symptoms until death of any cause. Laboratory findings were collected as the absolute nadir or the highest value reached during hospitalization. For categorical variables we applied Pearson's Chi-squared test or Fisher's exact test (if any value was n<5). Quantitative continuous variables were expressed as means and compared with Student's t test; categorical variables were expressed as number (%) and compared by Fisher's exact test. Pie charts were dropped to describe oncologic population. We used logistic regression to calculate the Odds Ratio (OR) and 95% confidence interval (95%CI) for dichotomic variables. All inferential analysis were performed using two-sided methods (α=0.05) and results were considered significant when p-values were <0.05. Statistical analysis was performed using STATA software, version14•2. (StataCorp LP, USA). Until April 19 th 287 patients had been screened and 90 required inpatient treatment due to COVID-19. We present here the first 63 consecutive oncologic patients that were admitted. Baseline clinicopathological characteristics of patients are shown in Table 1 . Regarding tumor characteristics and active oncologic therapies, most frequent primary tumor sites were lung cancer (27%) followed by colorectal (16%) and breast cancer (16%). [ Figure 1 ]. Disease was metastatic in 52 patients (88%) with more than 2 metastatic locations in 25% of them. Visceral and pulmonary tumor involvement was documented in 48% and 40% of cases respectively. Almost all (61 cases, 96%) were under active antitumor treatment, 58% of them were receiving chemotherapy-based regimens, 15% endocrine therapy, 11% targeted therapy and 12% were under immunotherapy. Fever (>38.5 ºC); was present in 89% of our cancer population, malaise was the second most related symptom (70%) followed by cough in 66% of cases. Some grade of dyspnea was reported by 45% of all subjects. Other previously described symptoms of Sars-CoV2 infection as rhinorrhea and hyposmia were less frequent symptoms in our series (8% and 18% respectively). Ninety-five percent had documented lung infiltrates in Chest X-ray or CT-Scan, among which 55% showed bilateral pneumonia. Six percent of the patients did not receive specific treatment, 27% were treated with LPV/r + HCQ + AZ and 67% received HCQ + AZ alone [ Table 6 ]. To the best of our knowledge, we present here the largest series of cancer patients undergoing active treatment admitted due to SARS-CoV-2 infection. COVID-19 pandemic spread is supposed to be major risk for cancer patients because of their frequent comorbidities and more susceptibility to infections due to immunosuppression derived from both neoplasm and oncologic therapies. To our best knowledge by mid April 2020 only 3 reports have been published focus on this population (4) (5) (6) . They all suggest that cancer patients are more likely to be infected and/or that COVID-19 infection is more severe than in general population (12) . In these reports, there is a lack of data regarding cancer patients undergoing active oncological therapies (comprising only from 22% to 41% of cases), as well as there is no detailed information regarding possible predictive factors for poor outcome. Our infected cancer patients were older (mean 66 years) than described both in East (13) and Western population (14) and similar to those from J.Yu et al (5) and L. Zhang et al (6) . Regarding previous condition, history of smoking habit was more frequent (11% current, 43% former smokers) than reported in non cancer patients from New York City Area or from mainland China (both around 15%); as well as COPD (22% in cancer patients, 5.4% in US population 3% in China). Other comorbidities like Hypertension, Cardiopathy or chronic kidney disease seems to be equally distributed among our cancer patients series and western population previously reported by Richardson et al (14) . The highest incidence of COVID-19 infection was found among lung cancer subjects and colorectal cancer patients. In our series 88% of infected patients presented with metastatic disease and 96% had received antitumor treatment within 4 weeks prior to infection, being chemotherapy-based regimens in more than 50% of them. Given that previously published data have suggested a higher risk of severe events for patients who underwent chemotherapy or surgery in weeks before the infection, our results could be of special relevance. Cancer patients under active oncological therapy show a higher mortality rate due to COVID-19 (25%) than previously reported for global population in China (1,4%)(13) but quite similar to actual death rate among hospitalized patients both in China (15) and New York City Area (24.5% and 25% respectively). In our series we found that only pulmonary tumor involvement (either primary or metastatic), severe neutropenia due to recent anticancer treatment and bilateral Sars-CoV-2 related pneumonia were statistically significant on multivariate analysis as independent mortality risk factors Interestingly, among cancer patients we found higher incidence of both respiratory failure (54%) and ARDS (38%) than previously reported being respiratory failure more frequent in those patients with previous anemia as well as among subjects with bilateral infiltrates (79%). In terms of primary tumor site, lung cancer patients accounted for 26% of all respiratory failure events. In our current series no single cancer patient underwent mechanical ventilation nor admitted to intensive Care Unit given limited resources at disease outbreak in Madrid, Spain, that were further reserved for non-comorbid patients. This could explain the fact that while our mortality rate is similar to studies with 14,2% (14) or 26% (15) Laboratory results in cancer patients were consistent with those from hospitalized noncancer patients, with up to 92% of lymphopenia, as well 95%, 98%, 83% and 96% of cases with LDH, CPR, ferritin and IL-6 levels above upper normal limits respectively. Hypoalbuminemia during hospitalization was documented in 84% of cancer patients in concordance with previous data (6) . Another interesting finding in our current report is linked to higher mortality associated to coagulopathy in SARS-Cov-2 infection (16) . Anticoagulant therapy has recently proved to collaborate to a favorable outcome among COVID-19 patients (17). VTE represents a highly frequent complication in cancer patients with SAR-Cov-2 infection with an overall rate of newly diagnosed VTE of 14% and a recurrence rate of 15% among previously diagnosed in our series. Even more concerning is that up to 20% of patients under chronic anticoagulation therapy a new VTE was found. Our multivariate logistic regression model has been able to identify several predictive factors of poor outcome both in terms of severe ARDS and death. Thus, presence of bilateral pneumonia, severe neutropenia, previous history of VTE or pulmonary tumor involvement should be considered in evaluation of COVID-19 cancer patient. SARS-CoV-2 infected cancer patients show worse outcomes in terms of mortality and severe respiratory failure than global population, but similar death rate to non-cancer patients hospitalized for this disease. Altered lymphocyte count, LDH, CR-P and albumin serum levels may discriminate illness severity. ARDS is the main cause of death and VTED screening as well as assessment of neutropenia, lung involvement and bilateral pneumonia at diagnosis are essential for the management of this high risk and fragile population. The authors wish to thank the patients, their families and all those health-care workers involved in this study, as well as to all cancer patients and their families suffering this disease. Funding sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis : JTH. 2020;18(5):1094-9. • Cancer patients are supposed to be specially vulnerable for Sars-CoV-2 infection. • Active cancer treatment could be deleterious in case of simultaneous SARS-CoV-2 infection • Outcomes of patients under treatment and admitted for SARS-CoV-2 infection are described • Hospitalized SARS-CoV-2 cancer patients show similar death rate to non-cancer patients. Clinical features of patients infected with 2019 novel coronavirus in Wuhan First Case of 2019 Novel Coronavirus in the United States Coronavirus disease (COVID-19) pandemic Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis Organization WH. Clinical Management of Severe Acute Respiratory infection (SARI) when COVID-19 disease is suspected, Interim Guidance COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis Clinical Characteristics of Coronavirus Disease 2019 in China Presenting Characteristics, Comorbidities, and Outcomes Among Patients Hospitalized With COVID-19 in the New York City Area Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Adjusted by Age, Sex, Cardiopathy, previous VTED Adjusted by Age, Sex, COPD, previous VTE, metastasis, ECOG. 8 djusted by Age, Sex, previous VTE Adjusted by Age, Sex, ECOG, metastasis, previous VTE Adjusted by Age, Sex, ECOG, metastasis, previous VTE